ESMO 2022 Industry Satellite Symposium

Triple Negative
Breast Cancer: An
Evolving Treatment
Landscape
Sunday,
11 September 2022
18:30 – 20:00 (CEST)

7.3.Q – Quimper Auditorium, Hall 7, Level 7.3

Paris Expo Porte de Versailles
Paris, France
Chair
Hope S. Rugo
Professor
Agenda
Department of Medicine
(Hematology/Oncology) 18:30 – 18:35 Introductions and objectives
Director
Breast Oncology and Hope S. Rugo
Clinical Trials Education
UCSF
San Francisco, CA, USA 18:35 – 18:55 Review of the evolving treatment
landscape in early TNBC
Faculty Peter Schmid

Rupert Bartsch 18:55 – 19:15 Review of the evolving treatment

Associate Professor
Medical University of Vienna
landscape in metastatic TNBC
Consultant Rupert Bartsch
Medical Oncology
Department of Medicine I
Clinical Division of Oncology 19:15 – 19:35 PD-L1 testing for metastatic TNBC
Medical University of Vienna
Vienna, Austria
Giuseppe Viale

Peter Schmid 19:35 – 19:45 Breast cancer patient case study

Clinical Director Hope S. Rugo
Breast Cancer Center
Barts Health NHS Trust
St. Bartholomew’s Hospital 19:45 – 19:55 Q&A from audience
London, England
Moderated by Hope S. Rugo
Giuseppe Viale
Director 19:55 – 20:00 Closing remarks
Department of Pathology and Hope S. Rugo
Laboratory Medicine
Division of Pathology
European Institute of Oncology (IEO) Agenda may be subject to change pending speaker confirmation
University of Milan
Milan, Italy

Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
All rights reserved. HQ-NON-00771 09/22 W3773970-2